🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.980
+0.070 (2.41%)
Nov 18, 2026, 4:00 PM EST - Market closed

Galectin Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.935.85.865.946.626.36
Research & Development
7.8614.2936.5732.1331.7423.82
Operating Expenses
14.7920.0942.4338.0738.3530.18
Operating Income
-14.79-20.09-42.43-38.07-38.35-30.18
Interest Expense
-6.72-7.33-5.54-2.79-1.03-0.49
Interest & Investment Income
0.120.130.340.230.050
Other Non Operating Income (Expenses)
-1.8-3.550.59-0.430.560.14
Pretax Income
-23.19-30.84-47.05-41.07-38.78-30.53
Net Income
-23.19-30.84-47.05-41.07-38.78-30.53
Preferred Dividends & Other Adjustments
0.180.140.153.740.10.17
Net Income to Common
-23.37-30.97-47.2-44.81-38.87-30.7
Net Income Growth
------
Shares Outstanding (Basic)
726462605959
Shares Outstanding (Diluted)
726462605959
Shares Change
12.88%2.56%3.57%1.29%1.48%2.63%
EPS (Basic)
-0.33-0.48-0.76-0.74-0.65-0.52
EPS (Diluted)
-0.33-0.48-0.76-0.74-0.65-0.52
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBIT
-14.79-20.09-42.43-38.07-38.35-30.18
SEC Filings: 10-K · 10-Q